CHAI selects Mylan subsidiary to provide HIV/AIDS treatment
PITTSBURGH The Clinton HIV/AIDS Initiative has selected a generic drug maker as its supplier of five antiretroviral drugs used in second-line treatment regimens under its UNITAID-funded projects in the developing world.
Mylan announced Monday that CHAI had selected India-based subsidiary Matrix Labs to supply the five drugs, which the company did not specify, as well as seven antiretroviral drugs used to treat children. Mylan owns 71.2% of Matrix.
“Facilitating patient access to affordable, quality treatments has helped transform AIDS from a fatal illness into a manageable chronic condition,” Mylan vice chairman and CEO Robert Coury stated. “Ensuring that access to these treatments continues to expand is a critical piece of solving this crisis.”
Vertex reports Q1 earnings
CAMBRIDGE, Mass. Vertex Pharmaceuticals ended first quarter 2009 with $869 million in cash, cash equivalents and marketable securities, the company announced Thursday.
The company is conducting a phase 3 study of telaprevir, a protease inhibitor for treating hepatitis C in patients who have not received treatment or for whom other treatments have failed. In March, Vertex started a phase 2a trial of VX-809, a compound designed to treat cystic fibrosis, and it also plans to start trials for the investigational CF drug VX-770 in the United States and Europe.
“With our strong performance in the first quarter, we are well-positioned to drive forward key programs in hepatitis C and cystic fibrosis and to deliver on our 2009 financial projections outlined earlier this year,” Vertex president Matt Emmens said. “Our top priority is to execute on the telaprevir phase 3 program and to prepare for [a new drug application] filing for telaprevir in the second half of 2010.”
Drug maker’s shares fall after HHS requests regulatory filing
NEW YORK A Department of Health and Human Services request that companies bidding on a government contract to provide anthrax vaccines give a regulatory plan to the Food and Drug Administration in 15 days caused shares of one of the companies to fall by 5.5% in afternoon trading on Friday, according to published reports.
The Associated Press reported Thursday that PharmAthene submitted a regulatory filing saying that HHS did not provide sufficient information. The HHS request caused PharmAthene’s shares to fall by 15 cents, to $2.56.
The Annapolis, Md.-based company makes the anthrax vaccine SparVax.